LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

4 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-01-31

Study Completion Date

2013-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the effectiveness of post-induction lenalidomide in patients with de novo AML with deletion 5q cytogenetic abnormality (del (5q)) or monosomy 5 (-5), who obtained complete remission after conventional induction chemotherapy. So, too, for those who no obtained response treatment (total resistance) or partial remission.

At the same time, the study evaluate the security of lenalidomide.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction

NCT01578954

Acute Myeloid Leukemia

COMPLETED PHASE1

A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q

NCT00885508

Myelodysplastic Syndrome Chronic Myelomonocytic Leukemia Acute Myeloid Leukemia

UNKNOWN PHASE2

Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5

NCT00761449

MDS AML

COMPLETED PHASE2

Lenalidomide In Patients With Acute Myeloid Leukemia

NCT00839059

Acute Myeloid Leukemia

TERMINATED PHASE1

Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities

NCT00546897

Leukemia, Myeloid, Acute

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

AML

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lenalidomine

Post-induction lenalidomide in patients with de novo AML with deletion 5q cytogenetic abnormality (del (5q)) or monosomy 5 (-5)

Group Type EXPERIMENTAL

Lenalidomide

Intervention Type DRUG

Initial dose of oral lenalidomide is 10 mg/day for 28 days every 28 days, during 6 months.

In case of response on day 169, patient will follow a treatment extension phase. The dose of lenalidomide should be the same as the last dose for initial phase, until 24 months or progression disease

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lenalidomide

Initial dose of oral lenalidomide is 10 mg/day for 28 days every 28 days, during 6 months.

In case of response on day 169, patient will follow a treatment extension phase. The dose of lenalidomide should be the same as the last dose for initial phase, until 24 months or progression disease

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Confirm the diagnosis of AML according to WHO criteria (Annex 4).
2. AML de novo (ie, patients without documented history of previous treatment with antineoplastic agents for radiotherapy or other oncological diseases, hematological or immunological, related to the development of secondary LMAs and secondary AML patients without primary MDS with del (5q) or -5 \[documented history of primary MDS with transformation to LMAs\]).
3. Diagnostic confirmation of the abnormality del (5q) or -5, with or without other cytogenetic abnormalities. It is not necessary that the del (5q) including band 5q31.
4. Patients who have received one cycle of induction chemotherapy consisting of a classical combination of anthracycline and cytarabine (with or without etoposide as a third agent associated), regardless of the response.
5. Patients have been evaluated the response to induction chemotherapy with anthracyclines and cytarabine (with or without etoposide as third agent partner) and were classified according to the criteria of IWG.20
6. ≤ 60 patients ineligible for allogeneic hematopoietic progenitors.
7. Patients\> 60 years are not eligible for allogeneic hematopoietic stem cell, or eligible but did not have HLA-identical brother.
8. Accept the use of any contraceptive method effective in patients of childbearing age with reproductive potential (see Section 6.5 on pregnancy prevention plan).
9. Ability to understand and voluntarily sign informed consent form.
10. Age ≥ 18 years at the time of signing the informed consent form.
11. Ability and willingness to follow the schedule of study visits.

Exclusion Criteria

1. AML secondary to treatment with cytostatic or immunosuppressive agents, myelodysplastic syndrome or other neoplastic disease.
2. AML with cytogenetic abnormalities t (15, 17), t (8; 21), t (16; 16) or inv (16) or their associated molecular rearrangements.
3. Patients who have received remission induction with a different regime to cytarabine anthracycline / - etoposide.
4. ≤ 60 patients eligible for allogeneic hematopoietic progenitors.
5. Patients\> 60 years eligible for allogeneic hematopoietic stem cell transplant and who have HLA-identical brother.
6. Patients who have not been evaluated the response to induction chemotherapy (complete remission, partial remission or resistance (see Table 6).
7. ECOG 3-4.
8. Any of the following laboratory abnormalities Serum creatinine\> 2.0 mg / dl (177 mmol / l). serum aspartate aminotransferase (AST) / glutamic oxalacetic transaminase serum (SGOT) or alanine aminotransferase (ALT) / serum glutamate pyruvate transaminase (SGPT)\> 5.0 x upper limit of normal (ULN).

total serum bilirubin\> 3 mg / dl.
9. Patient with known positive HIV serology. No HIV test is required in the process of selection.
10. Any severe psychiatric condition or disease that prevents the patient sign the informed consent form for the patient or involves an unacceptable risk should participate in the study.
11. Any serious organic disease or condition that behave for the patient if an unacceptable risk to participate in the study.
12. Previous use of cytotoxic chemotherapy agents or experimental agents (agents are not commercially available) for the treatment of AML.
13. Pregnant or breastfeeding (see Section 6.5 on pregnancy prevention plan).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No